Seeking In Vivo and In Vitro Models Exhibiting Resistance to Immune Checkpoint Inhibitors

Daiichi Sankyo, a global pharmaceutical company, is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors (ICIs).

Approaches of Interest:

• The mechanism of resistance (MoR) is clearly defined and is tumor-intrinsic 
• The PD-1 and PD-L1 immune checkpoint pathways are of highest interest
• Research focused on solid tumors (lung, breast and pancreatic tumors are of primary interest)
• The MoR to ICI reflects clinical observations 
• The MoR to ICI is associated with specific patient selection biomarker 

Out of Scope:

• Submissions relating to blood cancers 
• Opportunities that lack a clear MoR or have tumor-extrinsic MoR 

Developmental Stages of Interest:

• Opportunities from basic research to registration are in scope providing there is a clear MoR

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this submission form. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.